SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK). Colorectal cancer is among the most common malignancies worldwide. China has a high incidence of CRC, with over 500,000 new cases diagnosed annually. Approximately 83% of patients...